I thought it would be helpful to spread the trial information regarding an actively enrolling nationwide pre-exposure prophylaxis with weekly low-dose hydroxychloroquine (website: covidprep.umn.edu). Neat study design with eligibility determination, enrollment, and follow-up online as well as FedEx shipment of the medication. UMN also has a post-exposure prophylaxis trial ongoing, more information at covidpep.umn.edu.
This is a national, internet-based, randomized, double-blinded, placebo-controlled, prospective clinical trial examining the effectiveness of low-dose weekly hydroxychloroquine (HCQ) in preventing COVID-19 infection in high risk healthcare workers. Please find attached trial information sheet and enrollment eligibility email link. Trial information can also be found on Pre-exposure Prophylaxis for SARS-Coronavirus-2 - Full Text View - ClinicalTrials.gov. Feel free to share the trial information with your colleagues, academic connections, and through social media.
We hypothesized that weekly HCQ (same dose as the well-tolerated anti-malarial prophylactic dose) will decrease the risk of infection, and if infected, decrease the severity of the infection. This hypothesis is based on HCQ's mechanism of action on the endosomal entry pathway of SARS-CoV-2, preliminary clinical data of HCQ in COVID-19 treatment, in vitro antiviral properties, HCQ's high volumes of distribution resulting in high target organ (e.g. lung) steady state concentrations, and HCQ's known safety profile at its weekly dosage.
The trial will randomize participants into two treatment arms (once weekly dosing or twice weekly) and one placebo arm. Prophylaxis duration will be up to 12 weeks. Recruitment goal is set at 3,500 participants. Eligibility determination, enrollment, and weekly follow-up as well as post-trial follow-up will all be performed online, with no clinic visit or direct human contact. Eligible participants will receive overnight shipment of the medication vs. placebo. Primary endpoint is clinical or laboratory diagnosis of COVID-19.
Healthcare workers at high risk of COVID-19 exposure will be included in the study. People with active COVID-19 or suspected infection will be excluded and re-directed to other ongoing clinical trials. People with retinal disease, chronic kidney disease, G6PD deficiency, concurrent use of HCQ, HCQ allergy, on medication with potential QT prolongation, or on medication with known significant drug-drug interaction will be excluded.
We would like to know the answer sooner rather than later. And you can help us by spreading the trial information. If HCQ were truly prophylactic, we will be protecting our brave front-liners not only in the hospital but also from community asymptomatic spread. I would think protecting our critical medical staff is just as important as procuring PPE, ventilators, and bed capacity.
I wish we had Telemed as a specialty topic
I have been looking for work in Temed for years. The AAPA is now pushing to get us into the role and a new website
"Telehealth Many PAs have asked about opportunities in virtual medicine and telehealth. The Medicare program reimburses PAs for providing all covered telehealth services in the same manner as physicians. In response to the COVID-19 pandemic, the Centers for Medicare and Medicaid Services temporarily expanded telehealth and telemedicine services to enable beneficiaries to receive a wider range of healthcare services without having to travel to an office, clinic, or health care facility. PAs are fully included in the telehealth and telemedicine expansion program. PAs can find out more information about telehealth, telemedicine, and reimbursement at AAPA’s Reimbursement website. They may also be interested in joining AAPA’s special interest group, PAs in Virtual Medicine and Telemedicine (PAVMT)."
for PA interested in Telemed